A feasibility study of the metronomic chemotherapy using oral tegafur-uracil and cyclophosphamide for recurrent gynecological cancers

A feasibility study of the metronomic chemotherapy using oral tegafur-uracil and cyclophosphamide for recurrent gynecological cancers - A feasibility study of the metronomic chemotherapy using for recurrent gynecological cancers

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016438

Enrollment

Registered

2015-02-04

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advance and recurrent gynecological cancer

Interventions

UFT,cyclophosphamide,celecoxib

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) uterine, ovarian , fallopian tube and primary peritoneal cancer patients 2) platinum-resistant patients 3) Performance Status 0~2 4) measurable target lesion

Exclusion criteria

Exclusion criteria: 1) acute systemic inflammatory disease 2) uncontrolled cardiovascular disease 3) uncontrolled systemic disease 4) double cancers

Design outcomes

Primary

Measure	Time frame
Safety Disease Control Rate	—

Secondary

Measure	Time frame
Overall Survival Progression Free Survival Response Rate	—

Countries

Japan

Contacts

Public ContactKosei Hasegawa

Saitama Medical University International Medical Center Gynecologic Oncology

koseih@saitama-med.ac.jp042-984-4111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026